Transaction overview
Director Juan Jose Chacon Quiros sold 3,575 shares of common stock in Establishment Labs Holdings Inc. (NASDAQ: ESTA) on March 25, 2026. The shares transacted at prices between $60.00 and $60.32, yielding an average execution price of $60.075 and a total value of approximately $214,768.
Holdings after the sale
Following the sale, Chacon Quiros' reported holdings include 1,220,004 shares held indirectly through Sariel Group Ltd, plus 45,193 shares held directly.
Trading mechanics
The disposition was carried out under a pre-arranged Rule 10b5-1 trading plan.
Market movement
Since the transaction, the stock has traded lower, most recently quoted at $55.31, representing a decline of nearly 12% over the past week. Despite the recent pullback, shares are still higher by 41% over the prior six-month period.
Recent financial results
Establishment Labs released fourth-quarter 2025 financial results that surpassed analysts' projections. The company reported earnings per share of -$0.09, compared with a consensus forecast of -$0.22, representing a 59.09% positive surprise versus expectations. Quarterly revenue reached $64.6 million, topping the expected $63.75 million.
U.S. revenue for the quarter was $17.3 million. Management noted this component as part of a combined performance that produced a 45% year-over-year increase in total revenue. Gross margin expanded by 200 basis points to 70.5%, a shift the company attributed to a favorable mix in U.S. sales.
Analyst response
Following the results, Stephens raised its price target on Establishment Labs shares to $90 from $85 and maintained an Overweight rating.
Clear summary
- Director Juan Jose Chacon Quiros sold 3,575 Establishment Labs shares on March 25, 2026 for about $214,768 under a Rule 10b5-1 plan.
- After the sale, he holds 1,220,004 shares indirectly through Sariel Group Ltd and 45,193 shares directly.
- Establishment Labs' Q4 2025 results exceeded expectations on EPS and revenue; gross margin improved and Stephens raised its price target to $90, maintaining an Overweight rating.
Key points
- Insider sale executed under a pre-arranged 10b5-1 plan indicates a pre-determined disposition rather than an ad hoc trade - impacts corporate governance and investor relations.
- Q4 2025 results beat consensus on both EPS and revenue, with notable margin expansion and stronger U.S. revenue contributing to 45% year-over-year top-line growth - relevant to equity investors tracking earnings and revenue momentum.
- Analyst action tightened around a higher price target and maintained an Overweight rating, which may influence market sentiment among institutional and retail holders.
Risks and uncertainties
- Short-term stock volatility - the share price fell to $55.31, nearly 12% lower over the past week, which could affect market timing for investors responding to insider transactions.
- Concentration of holdings - a substantial indirect holding through Sariel Group Ltd means a large single-party exposure remains despite the sale, which could influence perceived insider alignment with minority shareholders.
- Forward expectations - while Q4 results beat estimates and an analyst raised its target, future performance and guidance are not addressed in these results, leaving uncertainty about sustainability of the recent momentum.
Bottom line
The March 25, 2026 sale by Director Juan Jose Chacon Quiros and the company's outperformance in Q4 2025 present concurrent data points for investors: a scheduled insider disposition alongside financial results that exceeded expectations and prompted an analyst to lift its price target.